British Society for Rheumatology > Knowledge > Excellence > Guidelines > Paediatric guidance

Paediatric guidance

Knowledge * Excellence * Guidelines * Paediatric guidance

These guidance notes have been ratified by the Council of the paediatric and adolescent rheumatology section within BSR and are designed to support those working in paediatric and adolescent care. Many of these documents have been produced in collaboration with other organisations, details of which can be found within each specific guideline.

 


British Society for Paediatric and Adolescent Rheumatology guidance:

BSPAR / ARMA standards of care for JIA

These Standards of Care are designed to help and support children and young people with JIA and their families and all professional teams, by providing a statement of the minimum standards of care required by such children and young people.

Find out more >

Guidance for screening for Uveitis in Juvenile Idiopathic Arthritis (JIA)

This guidance aims to reduce the incidence of visual impairment among children and young people with juvenile idiopathic arthritis (JIA) by early detection through screen allowing for early intervention.

Find out more >

Guidance on prescribing for children and young people

This guidance outlines standards and responsibilities for shared care protocol for immuno-modulating drugs

Find out more >

Guidance on methotrexate use in paediatric rheumatology

This guidance outlines information for health professionals in the use of methotrexate for children and young people

Find out more >

RCN guidelines:

Administering subcutaneous methotrexate for inflammatory arthritis

This is the third edition of the RCN’s guidance and has been updated to ensure the publication contains the latest evidence-based guidance to support practitioners in the safe and confident administration of subcutaneous methotrexate in a variety of primary and secondary care settings, including community and managed care environments. The guidance covers aspects of both adult and children/young people’s care.

Find out more >

Adolescent transitional care document

This guidance aims to help achieve a seamless transfer using a national clinical pathway framework and is divided into two parts – the first provides an overview of the issues to consider when planning transition services, and the second provides a practical framework for working with young people at each of the major phases of adolescence.

Find out more >

Assessing, managing and monitoring biologic therapies for inflammatory arthritis

This updated guidance is for rheumatology specialist practitioners and the wider health care team on assessing, managing and monitoring biologic therapies for inflammatory arthritis.

Find out more >

PRes and SHARE guidelines:

PReS (Paediatric Rheumatology European Association) and SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) have produced a number of recommendations on the management and treatment of conditions for paediatric and adolescent care.

View below the following recommendations:

Antiphospholipid syndrome

Find out more >

Autoinflammatory diseases

Find out more >

Dermatomyositis

Find out more >

Transitional care

Find out more >

Latest Tweet

@RheumatologyUK

New to #Twitter or want to meet fellow #tweeters? Join the official #Rheum2017 tweetup, BSR stand, 08:30, 25 Apr, exhibition hall

Contact us

British Society for Rheumatology
Bride House, 18-20 Bride Lane,
London EC4Y 8EE
T: +44 (0) 20 7842 0900
E: bsr@rheumatology.org.uk
Company No: 3470316
Charity No: 1067124
VAT No: 404 5637 66

Join us

We are the UK's leading specialist medical society for rheumatology and musculoskeletal professionals, and we welcome applications from all health professionals in these fields.